GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Total Assets

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Total Assets : $7.74 Mil (As of Sep. 2011)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Total Assets?

Poniard Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2011 was $7.74 Mil.

Total Assets is connected with ROA %. Poniard Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2011 was -170.20%. Total Assets is also linked to Revenue through Asset Turnover. Poniard Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2011 was 0.00.


Poniard Pharmaceuticals Total Assets Historical Data

The historical data trend for Poniard Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Total Assets Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.07 105.14 84.23 52.44 11.64

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.14 11.64 12.22 9.99 7.74

Poniard Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Poniard Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2010 is calculated as

Total Assets=Total Equity (A: Dec. 2010 )+Total Liabilities (A: Dec. 2010 )
=8.453+3.19
=11.64

Poniard Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2011 is calculated as

Total Assets=Total Equity (Q: Sep. 2011 )+Total Liabilities (Q: Sep. 2011 )
=3.117+4.619
=7.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poniard Pharmaceuticals  (OTCPK:PARD) Total Assets Explanation

Total Assets is connected with ROA %.

Poniard Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2011 is

ROA %=Net Income (Q: Sep. 2011 )/( (Total Assets (Q: Jun. 2011 )+Total Assets (Q: Sep. 2011 ))/ count )
=-15.084/( (9.989+7.736)/ 2 )
=-15.084/8.8625
=-170.20 %

Note: The Net Income data used here is four times the quarterly (Sep. 2011) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Poniard Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2011 is

Asset Turnover
=Revenue (Q: Sep. 2011 )/( (Total Assets (Q: Jun. 2011 )+Total Assets (Q: Sep. 2011 ))/ count )
=0/( (9.989+7.736)/ 2 )
=0/8.8625
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Poniard Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines